|
PL358271A1
(pl)
|
2000-03-06 |
2004-08-09 |
Warner-Lambert Company |
5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny
|
|
EP1373257B9
(en)
*
|
2001-03-29 |
2008-10-15 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
|
|
EP1562938B1
(en)
*
|
2002-11-04 |
2007-08-29 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl-pyrimidine derivatives as jak inhibitors
|
|
MX2007001126A
(es)
|
2004-07-27 |
2007-09-25 |
Sgx Pharmaceuticals Inc |
Moduladores de heterociclo cinasa de anillo fusionado.
|
|
US20060142312A1
(en)
|
2004-12-23 |
2006-06-29 |
Pfizer Inc |
C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
|
|
RU2008110902A
(ru)
|
2005-08-25 |
2009-09-27 |
Шеринг Корпорейшн (US) |
Агонисты адренорецепторов альфа а2с
|
|
MX2010013876A
(es)
|
2008-06-20 |
2011-03-04 |
Metabolex Inc |
Agonistas de arilo grpr119 y sus usos .
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
WO2010071846A2
(en)
|
2008-12-19 |
2010-06-24 |
Afraxis, Inc. |
Compounds for treating neuropsychiatric conditions
|
|
JO2885B1
(en)
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Ｅｇｆｒ 억제제 및 질환 치료방법
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
UY33226A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
EP2580213A4
(en)
|
2010-06-09 |
2013-12-25 |
Afraxis Holdings Inc |
8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
|
|
US20130252967A1
(en)
|
2010-06-10 |
2013-09-26 |
Afraxis, Inc. |
8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
|
|
EP2580215A4
(en)
|
2010-06-10 |
2014-01-15 |
Afraxis Holdings Inc |
8- (HETEROCYCYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
|
|
BR112013002112B1
(pt)
|
2010-07-29 |
2021-04-06 |
Rigel Pharmaceuticals, Inc. |
Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
|
|
CA2807498C
(en)
|
2010-08-05 |
2017-02-07 |
Temple University-Of The Commonwealth System Of Higher Education |
2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
WO2013175415A1
(en)
|
2012-05-23 |
2013-11-28 |
Piramal Enterprises Limited |
Substituted pyrimidine compounds and uses thereof
|
|
AR091876A1
(es)
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
DK2968290T3
(da)
|
2013-03-15 |
2019-11-25 |
G1 Therapeutics Inc |
Transient beskyttelse af normale celler under kemoterapi
|
|
WO2014144596A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
WO2015048547A2
(en)
|
2013-09-26 |
2015-04-02 |
Rigel Pharmaceuticals, Inc. |
Methods for using and biomarkers for ampk-activating compounds
|
|
US10016439B2
(en)
|
2014-01-31 |
2018-07-10 |
Ono Pharmaceutical Co., Ltd. |
Fused imidazole compounds
|
|
RU2671494C2
(ru)
|
2014-05-28 |
2018-11-01 |
Шанхай Фокон Фармасьютикал Ко., Лтд |
Некоторые ингибиторы протеинкиназы
|
|
CN105294655B
(zh)
|
2014-07-26 |
2019-03-15 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
KR20170032244A
(ko)
|
2014-07-26 |
2017-03-22 |
선샤인 레이크 파르마 컴퍼니 리미티드 |
Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
|
|
WO2016040858A1
(en)
*
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
US9969719B2
(en)
|
2015-03-11 |
2018-05-15 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
|
|
CN106608879A
(zh)
|
2015-10-27 |
2017-05-03 |
甘李药业股份有限公司 |
一种蛋白激酶抑制剂及其制备方法和医药用途
|
|
CN106810536A
(zh)
|
2015-11-30 |
2017-06-09 |
甘李药业股份有限公司 |
一种蛋白激酶抑制剂及其制备方法和医药用途
|
|
US11225492B2
(en)
|
2015-12-13 |
2022-01-18 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocycles useful as anti-cancer agents
|
|
CN108779117B
(zh)
|
2015-12-27 |
2021-08-31 |
重庆复创医药研究有限公司 |
一类激酶抑制剂
|
|
WO2017133701A1
(en)
|
2016-02-06 |
2017-08-10 |
Shanghai Fochon Pharmaceutical Co., Ltd. |
Certain protein kinase inhibitors
|
|
CN107286180B
(zh)
|
2016-04-11 |
2019-07-02 |
上海勋和医药科技有限公司 |
杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
|
|
CN107286134B
(zh)
|
2016-04-11 |
2019-04-12 |
上海勋和医药科技有限公司 |
2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用
|
|
HUE064145T2
(hu)
|
2016-04-15 |
2024-03-28 |
Epizyme Inc |
Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok
|
|
WO2017185031A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
US10835535B2
(en)
|
2016-05-07 |
2020-11-17 |
Shanghai Fochon Pharmaceutical Co., Ltd. |
Certain protein kinase inhibitors
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
EP3858835A1
(en)
|
2016-07-01 |
2021-08-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based antiproliferative agents
|
|
JP7106462B2
(ja)
|
2016-07-01 |
2022-07-26 |
ジー１ セラピューティクス， インコーポレイテッド |
Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
EP3505519B1
(en)
|
2016-11-11 |
2022-01-05 |
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines
|
|
ES2917377T3
(es)
|
2016-12-22 |
2022-07-08 |
Betta Pharmaceuticals Co Ltd |
Derivados de benzimidazol, procedimientos de preparación y utilizaciones de los mismos
|
|
CN107382974B
(zh)
|
2017-06-08 |
2020-06-05 |
扬州市三药制药有限公司 |
一种嘧啶胺类化合物作为周期蛋白依赖性激酶4/6抑制剂的应用
|
|
CA3088381A1
(en)
|
2018-01-29 |
2019-08-01 |
Beta Pharma, Inc. |
2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
|
|
US11479555B2
(en)
|
2018-02-23 |
2022-10-25 |
Newave Pharmaceutical Inc. |
Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
|
|
WO2020006210A1
(en)
|
2018-06-27 |
2020-01-02 |
Tufts Medical Center, Inc. |
Pyridopyrimidine compounds and methods of their use
|
|
WO2020023480A1
(en)
|
2018-07-23 |
2020-01-30 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
BR112021001499A2
(pt)
|
2018-07-27 |
2021-04-27 |
California Institute Of Technology |
inibidores de cdk e usos dos mesmos
|
|
CN110835334B
(zh)
|
2018-08-16 |
2022-10-18 |
中国药科大学 |
吲哚取代唑类化合物及其用途
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
WO2020108661A1
(zh)
|
2018-11-30 |
2020-06-04 |
杭州英创医药科技有限公司 |
作为cdk-hdac双通路抑制剂的杂环化合物
|
|
CN113166110B
(zh)
|
2018-12-12 |
2023-08-11 |
暨南大学 |
2-氨基嘧啶类化合物及其应用
|